Traditionally, the classification of breast cancer relies on the expression of
immunohistochemical (IHC) biomarkers readily available in clinical practice. Using highly …

The findings discussed in this review have significant implications for clinical practice and
research in TNBC. The identification of distinct molecular subtypes through gene expression …

Background Efficacy of endocrine therapy in HR+/HER2− metastatic breast cancer could
differ depending on the presence of BRCA1/2 germline mutation. Methods The ESME …

Die in den letzten Jahren begonnenen großen Studienprogramme zu den CDK4/6-
Inhibitoren, den zielgerichteten Therapien und den Antikörper-Medikament-Konjugaten …

Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical
Research Institute (FRCB-IDIBAPS), Barcelona, Spain; 4Faculty of Medicine and Health …

Für Patientinnen wie auch Patienten mit hormonrezeptorpositivem (HRpos)/Human
epidermal growth factor receptor 2-negativem (HER2neg) Mammakarzinom wurden in den …

Invasive lobular breast cancer (ILC) presents unique challenges and considerations in the
realm of surgical management. Characterized by its distinct histological features, including …

Mit den Zulassungen von Abemaciclib (monarchE-Studie) und Olaparib (OlympiA-Studie) in
der adjuvanten Therapiesituation haben sich die Therapiestandards bei der Behandlung …

Die in den letzten Jahren begonnenen großen Studienprogramme zu den CDK4/6-
Inhibitoren, den zielgerichteten Therapien und den Antikörper-Medikament-Konjugaten …

The treatment of patients with breast cancer is making noteworthy strides in several clinical
settings, with recent trial results showing overall survival (OS) improvements for advanced …